CClinicalTrials.gg
CompletedNCT03500796Updated May 19, 2021

Combined Amniotic Membrane and Platelet Rich Plasma Clot for Management of Central Corneal Perforation

An interventional study of Platelet rich plasma clot implantation and Wound closure with amniotic membrane in Corneal Perforation, sponsored by Minia University. Completed at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2021-05-19.

Sponsored by Minia University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Sex
All
01

Study summary

Use of amniotic membrane(AMT) and platelet rich plasma (PRP) clot for closure of central corneal perforation

Read the detailed description

Use of amniotic membrane and platelet rich plasma clot for closure of central corneal perforation either post infective or posttraumatic

02

Conditions studied

  • Corneal Perforation
03

In context

Lead sponsor

Minia University is the lead sponsor of 356 studies on the registry; 115 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • central corneal perforation

Exclusion criteria

Exclusion Criteria:

  • active infection
  • posterior segment pathology
  • non seeing eye
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Other
    Corneal perforation patients

    Patients who had/impeding corneal perforation due to melting of the cornea after infection with a corneal pathogen (bacterial or viral), with no previous surgical intervention. Patients will undergo: Platelet rich plasma clot implantation Wound closure with amniotic membrane

    Procedure: Platelet rich plasma clot implantation · Procedure: Wound closure with amniotic membrane

Interventions

  • ProcedurePlatelet rich plasma clot implantation

    Implantation of a platelet rich plasma clot, which is created from the plasma of the patients, and refrigerated to be inserted under the sealing amniotic membrane

  • ProcedureWound closure with amniotic membrane

    Closure of the corneal perforation with a synthetic amniotic membrane with a 2 mm safety margin

06

What researchers measure

Primary outcomes

  1. Closure of the corneal wound

    sealing of the edges corneal gap, with formation of scar tissue

    Time frame: 3 months

07

Study locations

1 site
  • Faculty of Medicine
    Minya, Egypt
08

References and documents

Individual participant data

Plan to share: No — steps of technique and results

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03500796
Lead sponsor
Minia University
Responsible party
Ahemd Abdelghany (Lecturer of Ophthalmology, Faculty of Medicine, Minia University) — Principal investigator
First posted
Apr 18, 2018
Start date
Apr 15, 2018
Primary completion
Dec 31, 2020
Completion
Dec 31, 2020
Last update
May 19, 2021

Study contacts

Ahmed A Abdelghany, MD
principal investigator · Assistant professor of Ophthalmology, Faculty of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion